SK bioscienceLtd (KOSE:A302440) - Share price, News & Analysis

A302440 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	4/6
Financial Health	5/6
Dividends	0/6

A302440 Stock Overview

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally.

Rewards

Trading at 45.2% below our estimate of its fair value

Earnings are forecast to grow 19.4% per year

Earnings grew by 979.8% over the past year

Risk Analysis

No risks detected for A302440 from our risk checks.

SK bioscienceLtd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for SK bioscienceLtd
Historical stock prices
Current Share Price	₩121,500.00
52 Week High	₩362,000.00
52 Week Low	₩115,000.00
Beta	0
1 Month Change	-10.99%
3 Month Change	-19.27%
1 Year Change	-24.77%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-28.11%

Shareholder Returns

	A302440	KR Biotechs	KR Market
7D	1.3%	0.8%	3.2%
1Y	-24.8%	-38.0%	-14.6%

Return vs Industry: A302440 exceeded the KR Biotechs industry which returned -38% over the past year.

Return vs Market: A302440 underperformed the KR Market which returned -14.6% over the past year.

Price Volatility

Is A302440's price volatile compared to industry and market?
A302440 volatility
A302440 Average Weekly Movement	6.6%
Biotechs Industry Average Movement	6.6%
Market Average Movement	5.6%
10% most volatile stocks in KR Market	10.4%
10% least volatile stocks in KR Market	3.2%

Stable Share Price: A302440 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: A302440's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2018	n/a	Jae-Yong Ahn	https://www.skbioscience.co.kr

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children.

SK bioscienceLtd Fundamentals Summary

How do SK bioscienceLtd's earnings and revenue compare to its market cap?
A302440 fundamental statistics
Market Cap	₩9.60t
Earnings (TTM)	₩355.14b
Revenue (TTM)	₩929.00b

26.3x

P/E Ratio

10.0x

P/S Ratio

Is A302440 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
A302440 income statement (TTM)
Revenue	₩929.00b
Cost of Revenue	₩358.97b
Gross Profit	₩570.03b
Other Expenses	₩214.89b
Earnings	₩355.14b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	4.63k
Gross Margin	61.36%
Net Profit Margin	38.23%
Debt/Equity Ratio	5.9%

How did A302440 perform over the long term?

See historical performance and comparison

Valuation

Is SK bioscienceLtd undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

45.2%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: A302440 (₩121500) is trading below our estimate of fair value (₩221704.11)

Significantly Below Fair Value: A302440 is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: A302440 is poor value based on its PE Ratio (26.3x) compared to the KR Biotechs industry average (25.4x).

PE vs Market: A302440 is poor value based on its PE Ratio (26.3x) compared to the KR market (14.4x).

Price to Earnings Growth Ratio

PEG Ratio: A302440 is poor value based on its PEG Ratio (1.4x)

Price to Book Ratio

PB vs Industry: A302440 is overvalued based on its PB Ratio (5.8x) compared to the KR Biotechs industry average (3.3x).

Future Growth

How is SK bioscienceLtd forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

19.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A302440's forecast earnings growth (19.4% per year) is above the savings rate (3.5%).

Earnings vs Market: A302440's earnings (19.4% per year) are forecast to grow faster than the KR market (14.8% per year).

High Growth Earnings: A302440's earnings are forecast to grow, but not significantly.

Revenue vs Market: A302440's revenue (18.3% per year) is forecast to grow faster than the KR market (9.6% per year).

High Growth Revenue: A302440's revenue (18.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A302440's Return on Equity is forecast to be low in 3 years time (15.1%).

Past Performance

How has SK bioscienceLtd performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

979.8%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: A302440 has high quality earnings.

Growing Profit Margin: A302440's current net profit margins (38.2%) are higher than last year (14.6%).

Past Earnings Growth Analysis

Earnings Trend: Unable to establish if A302440's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare A302440's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.

Earnings vs Industry: A302440 earnings growth over the past year (979.8%) exceeded the Biotechs industry 37.5%.

Return on Equity

High ROE: A302440's Return on Equity (22.2%) is considered high.

Financial Health

How is SK bioscienceLtd's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: A302440's short term assets (₩1,837.8B) exceed its short term liabilities (₩460.0B).

Long Term Liabilities: A302440's short term assets (₩1,837.8B) exceed its long term liabilities (₩48.9B).

Debt to Equity History and Analysis

Debt Level: A302440 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if A302440's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: A302440's debt is well covered by operating cash flow (563.9%).

Interest Coverage: A302440's interest payments on its debt are well covered by EBIT (248.2x coverage).

Balance Sheet

Dividend

What is SK bioscienceLtd current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A302440's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A302440's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A302440's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A302440's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A302440 has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average board tenure

CEO

Jae-Yong Ahn (54 yo)

1.17yrs

Tenure

Mr. Jae-Yong Ahn is the Chairman, Chief Executive Officer and President of SK bioscience Co.,Ltd since March 2021. He serves as Executive Officer and Director of VAX Business Division at SK Discovery Co.,...

Board Members

Experienced Board: A302440's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/19 00:00
End of Day Share Price	2022/05/19 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31